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1. Introduction  
Today, more than 25 years after the description of the first AIDS cases in children, major 
advances have been made on the prevention and treatment of the infection caused by 
human immunodeficiency virus (VIH-1), mainly after the availability of highly active 
antiretroviral therapy (HAART). Despite improved access to antiretroviral treatment and 
prevention, the HIV-infection epidemic continues to expand. The progression of the disease 
is much faster in children than in adults as well as the risk of complications. Since most 
infections occur perinatally, the virus overcomes the capacity of the immature immune 
system to control the HIV replication and dissemination occurs to all organ systems 
including the central nervous system (CNS). As a consequence the clinical course is more 
accelerated in children than in adults, and the immunological dysfunction is greater. 
Without antiretroviral treatment, HIV-infection in children has a bimodal pattern: a rapidly 
progressive form (15-20%) characterized by the development of severe opportunistic 
infections (OI), encephalopathy and death in the first 3 years, and a second form less 
aggressive and more alike to the presentation seen in adults, that accounts for around 80% 
of cases. Furthermore as there are no accurate prognostic surrogate markers of disease 
progression at diagnosis, most children should be treated early. Nevertheless, there is a 
delay in the development and implementation of antiretroviral treatment in children and 
adolescents. In addition, the need for a lifelong medication, with complex schedules, 
frequent high pill burden and lack of suitable paediatric formulation with insufficient data 
for children makes more difficult to maintain a permanent adherence to medication. 
Currently, although most children are on a stable situation with high CD4 counts and 
complete control of viral replication, the long-term consequences of the disease and of the 
accumulated effects of HAART are unknown and of major concern.  
2. Clinical manifestations of HIV-infection in the era of HAART 
The mortality and morbidity in HIV-infected children has declined since 1996 with the 
introduction of HAART. The studies comparing pre-HAART and post-HAART era marked 
a significant difference with a reduction in rates of mortality and progression to AIDS 
(Brady et al., 2010, Sánchez Granados J, 2003). The hospitalization has markedly decreased 
in HIV-infected children who have access to HAART. Frequent causes of hospitalization like 
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bacterial infections and opportunistic infections have diminished after introduction of 
HAART (Puthanakit et al., 2007). Many children died of Pneumocystis carinii pneumonia 
whereas others succumbed to a variety of opportunistic infections, including disseminated 
cytomegalovirus, disseminated Mycobacterium avium complex (MAC) and recurrent, severe 
bacterial infections (Abrams, 2000). Opportunistic infections and other related infections are 
uncommon in children in the HAART era in developed countries (Gina et al., 2006). On the 
other hand, children with persistently low CD4 percentage are at risk for opportunistic 
illnesses (Ylitalo et al., 2006). Children who experienced opportunistic infections have higher 
mortality rates than do those who do not (Nesheim et al., 2007). The incidence of bacterial 
infections have decreased in the post-HAART era, as well as the time elapsed to the first 
bacteraemia episode has been prolonged, although children with a decline of CD4 T cells are 
still more likely to develop bacteraemia (Kapogiannis et al., 2008). Nevertheless, severe 
bacterial infectious still occurred at considerable high rates, even in the absence of a severe 
CD4 cell depletion (Chiappini et al., 2007). Antimicrobial prophylaxis has resulted in a 
successful prevention of several opportunistic infections in children with low CD4 cells. 
Since the advent of HAART has led to an increase the numbers of CD4 T cells and CD4 
percentage to a level of lower risk in children, there is the possibility of safe discontinuation 
of prophylaxis for opportunistic infections once HIV-infected children demonstrate 
improvement in CD4 cell counts to levels at which such prophylaxis would not be initiated 
according to current guidelines (Nachman et al., 2005). Organ-specific diseases such as 
cardiomyopathy, nephropathy, encephalopathy, and others contribute substantially to the 
morbidity and mortality associated to with HIV infection. HAART results in a resolution of 
most of these organ-specific complications (Saulsbury, 2001). Other organ-specific diseases 
like, thrombocytopenia, wasting syndrome and lymphoid interstitial pneumonia, have 
dropped dramatically since the introduction of HAART (Guillén et al., 2010) and are also 
improved with effective antiretroviral therapy. As survival has been prolonged in 
perinatally HIV-infected children and adolescents in the HAART era and many of them are 
now reaching adulthood, an increase in the incidence rates over time in pregnancy-related 
conditions and gynaecological dysplasia is being observed in parallel with a decrease of the 
incidence of the other non infectious conditions. (Nachman et al., 2009).  
 
Clinical 
N A B C 
 
Asymptomatic 
Mild 
symptoms 
Moderated 
symptoms 
Severe 
Symptoms 
Immunological*     
 - Not significant 
immunodeficiency1 
N1 A1 B1 C1 
 - Moderate 
immunodeficiency2 
N2 A2 B2 C2 
 - Severe 
immunodeficiency3 
N3 A3 B3 C3 
Table 1. Clinical and immunological stages (CDC 1993) 
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In 1994, the CDC proposed a classification of HIV-disease in children into 4 clinical 
categories (N, A, B, C) and 3 immunological categories (1, 2, 3), according to the degree of 
immunosuppression (CDC, 1994) (Table 1). In developing countries, WHO classification also 
considers 4 clinical categories according to severity and 3 immunological categories (WHO, 
2007)(Table 2). There are a variety of OI and organ-specific diseases in different clinical 
classification and AIDS events. Since the CD4 absolute numbers decline physiologically 
from birth and the CD4 percentage is more preserved across ages, this parameter is 
preferred in children below 6 years of age, as it is a better predictor of disease progression. 
The absolute number of CD4 cells does not predict accurately the risk of complications like 
in adults, although the degree of immunosuppression influences the occurrence of an 
infection event or development of an organ-specific involvement. 
 
*     < 12 moths 1-5 years 6-12 years 
1CD4 > 1500/mm3, > 25% >1000/mm3, > 25% > 500/mm3, >25% 
2CD4 750-1499/mm3, 15-
24% 
500-999/mm3, 15-
24% 
200-499/mm3, >15-
24% 
3CD4 < 750/mm3, < 15% <500/mm3, < 15% < 200/mm3, < 15% 
Table 1. Centers for Diseases Control. 1994 revised classification system for HIV infection in 
children less than 13 years of age. (CDC, 1994) 
2.1 Impact of HAART on organ-specific diseases 
In developed countries, HAART has dramatically changed the natural history of HIV 
infection in children. HAART has reduced the morbidity and mortality among HIV-infected 
children leading to substantial increase in CD4 T-lymphocyte count and a parallel decrease 
in HIV viral load. Perinatally-acquired HIV-infection has become a chronic disease, in which 
many infected children in developed countries are entering adolescence and adulthood.  
There are a variety of organ-specific diseases in different clinical classification and AIDS events 
classified in the CDC and WHO classifications (Tables 1 and 2).  The most frequent organ-
specific diseases in pre HAART era in children were encephalopathy, cardiomyopathy, 
wasting syndrome, lymphoid interstitial pneumonia, thrombocytopenia and nephropathy. 
Most of them occur in advanced stages of immunosuppresion, although sometimes they may 
present as the initial manifestation of the disease, even with relatively preserved CD4 cell 
count or CD4 percentage. With successful HAART, the weight and height growth curves tend 
to normalize over time. In addition, the incidence of organ-specific diseases has dramatically 
decreased with the use of HAART. Most organ-specific diseases improve with HAART, and in 
many cases the organ-function is completely restored.  
2.1.1 Category A organ-specific diseases 
Hepatomegaly is a common clinical manifestation of paediatric HIV disease and is likely 
caused by the replication of HIV within the reticuloendothelial system. In HIV-infected 
children a variety of factors may be involved in hepatomegaly besides HIV itself, like 
concomitant hepatitis viruses, opportunistic infections, medications and malnutrition. 
Generalized lymphadenopathy is another common clinical finding in HIV-infected children, 
but a differential diagnosis must be done with other viral infections, opportunistic and 
mycobacterial infections, and malignancy.  
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Clinical stage 1 
Asymptomatic 
Persistent generalized lymphadenoapathy 
Clinical stage 2 
Unexplained persistent hepatosplenomegaly 
Papular pruritic eruptions 
Fungal nail infections 
Angular cheilitis  
Lineal gingival erythema 
Extensive wart virus infection 
Unexplained persistent parotid enlargement 
Extensive molluscum contagiosum 
Recurrent oral ulceration 
Unexplained persistent parotid enlargement 
Herpes zoster 
Recurrent of chronic upper respiratory tract infections (otitis media, otorrhoea, sinusitis, 
tonsillitis) 
Clinical stage 3 
Unexplained moderate malnutrition or wasting not adequately responding to standard 
therapy 
Unexplained persistent diarrhoea (14 days or more) 
Unexplained persistent fever (above 37.6ºC, intermittent or constant, for longer than one 
month) 
Persistent oral candidiasis (after 6-8 weeks of life) 
Oral hairy leukoplakia 
Acute necrotizing ulcerative gingivitis or periodontitis 
Lymph node tuberculosis 
Pulmonary tuberculosis 
Severe recurrent bacterial pneumonia 
Symptomatic lymphoid interstitial pneumonitis 
Chronic HIV-associated lung disease including bronchiectasis 
Unexplained anaemia (<8.0g/dl), neutropaenia (<0.5x109/L3) and or chronic 
thrombocytopenia (<50 x 109/L3) 
Clinical stage 4 
Unexplained severe wasting, stunting or severe malnutrition not responding to standard 
therapy 
Pneumocystis pneumonia 
Recurrent severe bacterial infections (e.g. empyema, pyomyositis, bone or joint infection, 
meningitis, but excluding pneumonia) 
Chronic herpes simplex infection; (orolabial or cutaneous of more than one month’s 
duration, or visceral at any site) 
Extrapulmonary TB 
Kaposi sarcoma 
Oesophageal candidiasis (or candiadisis of trachea, bronchi or lungs) 
Central nervous system toxoplasmosis (after the neonatal period) 
HIV encephalopathy 
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Cytomegalovirus (CMV) infection; retinitis or CMV infection affecting another organ, 
with onset at age more than 1 month 
Extrapulmonary cryptococcosis including meningitis 
Disseminated endemic mycosis (extrapulmonary histoplasmosis, coccidioidomycosis, 
penicilliosis) 
Chronic cryptosporidiosis (with diarrhoea) 
Chronic isosporiasis 
Disseminated non-tuberculous mycobacterial infection 
Cerebral or B cell non-Hodgkin lymphoma 
Progressive multifocal leukoencephalopathy 
HIV-associated cardiomyopathy or nephropathy 
Table 2. WHO clinical staging of HIV for infants and children with established HIV 
infection. (WHO, 2007) 
Parotid swelling is thought to be caused by the HIV virus itself, although EBV may also play 
a role. Suppurative bacterial parotiditis is rare in HIV-infected children. Although very 
inusual, in progressive parotid swelling a malignancy must also be considered in the 
differential diagnosis. 
Dermatitis in children can be secondary to infections or due to medications. The most 
common non-infectious diseases are atopic dermatitis and seborrheic dermatitis.  
These manifestations are still common but less frequently observed since the introduction of 
HAART. In addition they all tend to improve or even disappear with the use of HAART 
2.1.2 Category B organ-specific diseases 
Hematologic disorders like anemia, neutropenia and thrombocytopenia more than 30 days of 
duration are category B manifestations. These manifestations can occur for many reasons like 
peripheral destruction, the most common cause of the HIV-associated thrombocytopenia, 
adverse effect of medications (zidovudine) or medications to treat opportunistic infections 
(ganciclovir), by HIV virus itself, nutritional status and changes in the bone marrow associated 
with chronic illness. Various studies have demonstrated a reduction in thrombocytopenia and 
other cytopenias when HAART is started.  
Dilated cardiomyopathy has been described in 10%-20% of children with HIV infection. The 
mean age at diagnosis of cardiomyopathy in children is 18-24 months, but symptomatic 
cardiomyopathy may occur in children who are as young as 6 months age. Patients with 
dilated cardiomyopathy have been preceded by myocarditis, due to direct infection of 
myocardial cells by HIV. The resolution of this cardiomiopathy after introduction HAART 
has been described, with complete restoration of ventricular ejection fraction. Although 
cardiomyopathy appears to be rare nowadays in developed countries, it is not uncommon in 
children coming from high-prevalence areas with advances states of immunosuppression. In 
these patients a cardiac ultrasound is recommended as baseline evaluation. 
Leiomyosarcoma is described in HIV-infected children, but the incidence is very low. The 
proportion of leiomyosarcoma or leiomyoma in HIV-infected children is 17% of all cancers 
in these children. Smooth-muscle tumors are reported in the gastrointestinal tract, liver, 
spleen and lung. In HIV-infected children these tumors are strongly associated to Epstein-
Barr virus. In a study of malignancy in HIV-infected children no significant differences were 
found in the overall rates of soft tissue cancer between HIV-infected children and uninfected 
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children. Leiomyosarcoma was the only soft tissue cancer to occur in HIV-infected children 
whereas various different soft tissues sarcomas occurred in non-infected children. (Kest et 
al., 2005). 
Lymphocitic interstitial pneumonia (LIP) is common in HIV–infected children non-treated 
with HAART. The etiology is unknown but it has been suggested that the coinfection with 
Epstein-Barr virus and HIV may result in a lymphoproliferative response. The patients are 
initially asymptomatic or have mild symptoms. They may include cough, mild tachypnea 
and in advanced stages hypoxemia. The course is usually complicated with recurrent 
episodes of acute lower respiratory tract infections frequently leading to bronchiectasis. The 
chest radiography usually shows a diffuse reticulonodular pattern more pronounced 
centrally. High resolution CT may improve the diagnostic accuracy; typical features include 
micronodules 1-3 mm in diameter, with a perylymphatic distribution, and subpleural 
nodules. Lung biopsy may show interstitial infiltrate of lymphocytes and lymphoid 
aggregates surrounding the airways. LIP has been associated with chronic liver disease and 
bilateral parotid enlargement. Treatment is symptomatic. Oral corticosteroids have been 
used. HAART has been described to improve the respiratory status in adults and has been 
reported to be associated with the resolution of radiographic abnormalities in children.  LIP 
is a stage 3 of WHO AIDS defining illness it is an indication to start HAART in children who 
are not received antiretroviral treatment. (Zar, 2007). 
Nephropathy prevalence varies from 2% to 10% in HIV-infected children, and has been 
reported to be more common in African-American children than Hispanic or white HIV-
infected children. The clinical presentation varies from asymptomatic proteinuria to 
symptomatic renal tubular acidosis, hematuria, proteinuria and acute renal failure. 
Nephropathy is associated with a higher degree of immunosupresion and a higher 
mortality. Biopsy diagnosis can reveal the typical histologic features of minimal change 
nephritic syndrome, mesangioproliferative glomerular lesions, and “lupus-like” renal 
lesions. Other patients show renal changes consistent with the diagnosis of HIVAN (HIV-
associated nephropathy) or HIV-immune complex disease (HIVICK). The introduction of 
HAART has revolutionized the clinical management of HIV-associated renal disease. The 
use of HAART is associated with a marked improvement of HIVAN, resulting in slower 
progression to end-stage renal disease or even in recovery from dialysis-dependent renal 
failure provided the kidney damage is not too severe (Mc Culloch et al., 2008).  
2.1.3 Category C organ-specific diseases 
Encephalopathy has been reported between 13-35% of children with HIV infection and in 
35-50% of children with AIDS. Studies have demonstrated that HIV enters the central 
nervous system (CNS) soon after the infection and may persist in this compartment over the 
entire course of HIV infection. Mechanisms of pediatric HIV neuropathogenesis and factors 
associated with neurodevelopmental abnormalities in perinatally infected children are not 
yet fully understood. Neurotropic HIV likely develops distinct genotypic characteristics in 
response to this unique environment. (Van Rie et al., 2007). Complementary studies are 
usually non-specific, in fact the isolation of HIV from cerebrospinal fluid does not correlate 
with clinical symptoms. Neuroimaging has provided the best evaluation showing cortical 
atrophy with abnormalities in the subcortical white matter and in basal ganglia regions. The 
use of HAART is highly effective in reducing the incidence of HIV encephalopathy among 
perinatally infected children. CNS-penetrating antiretroviral regimens are important in 
affecting survival after diagnosis of HIV encephalopathy (Patel el al., 2009). 
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Malignancy prevalence in HIV infected children is significantly higher than in the normal 
population, approximately 2% compared with 1%. The types of malignancy reported show 
the following proportions of malignancies: 65% non-Hodgkin´s lymphoma, 17% 
leiomyosarcoma or leiomyoma, 8% leukemia, 5% Kaposi´s sarcoma, 3% Hodgkin´s 
lymphoma and less than 2% vaginal carcinoma in situ and tracheal neuroendocrine 
carcinoma. Non-Hodgkin´s lymphoma occurred most commonly in the gastrointestinal tract 
(37%), followed by the CNS (17%), liver and spleen involvement were common sites too. 
Although the immunosupresion of HIV disease in cancer pathogenesis is recognized, the 
etiology of cancer in paediatric HIV infection is not well-understood. In one study, a high 
viral load of Epstein-Barr virus was associated with the development of malignancy, but 
only in children with CD4 T cells counts > 200/μl (Pollock et al., 2003). In other study, the 
incidence of cancer in HIV infected children was highest in patients who received HAART 
less than 2 years compared to children with more than 2 years of HAART. (Kest et al., 2005) 
The wasting syndrome has been described in HIV infected children. The relationship 
between protein-energy malnutrition and adverse effects on the immune system result in 
immune deficiency states. Malnutrition may exacerbate the immunological effects. The 
causes of malnutrition in HIV children include decreased nutrient intake, gastrointestinal 
malabsorption, increased nutritional requirements or tissue catabolism and psychosocial 
factors, as well as medications and infections that may also cause malnutrition. HAART has 
decreased the incidence of wasting syndrome, but new side effects like lipodystrophy has 
been well defined in children (Miller, 2003). HIV-infected children have experienced 
significant improvement on growth since the introduction of HAART. An increase in the 
mean of weight z-scores to normal values was obtained by week 48 and an increase in mean 
height z-scores approached normal values by 96 week (Verweel et al., 2002; Guillén et al., 
2007) 
2.2 Impact of HAART on bacterial and opportunistic infections 
Bacterial infections and OI infections still occur in the HAART era in children, mostly in 
those with persistently low CD4 T lymphocyte counts caused by failure of adherence to 
multiple drugs or drug resistance. By contrast, OI and serious bacterial infections, herpes 
zoster and tuberculosis (TB) continue to present in children who are not severely 
immunocompromised. The incidence of OI is higher in developing countries, where the use 
of HAART is less extended, the follow-up more difficult and the socioeconomic conditions 
worse.  
In contrast with adults, OI in children usually reflect a primary infection by a pathogen, 
whereas in adults they are often secondary to reactivation from latent infections. Perinatal 
transmission of hepatitis C virus and cytomegalovirus are more frequent in HIV-infected 
women than in non-infected women. Children undiagnosed of HIV infection are at risk to 
suffer an OI because of the lack of HAART and primary prophylaxis. Besides, in children 
the diagnosis of OI in some situations is difficult. In the first moths of live it is not possible 
to distinguish between specific antibodies against common pathogens and antibodies 
belonging to the mother due to transplacental transfer. Furthermore, the diagnostic yield for 
many OI in children is usually lower than in adults and requires admission or invasive 
procedures. TB diagnosis requires obtaining smears of induced sputum or gastric lavage, 
with lower sensitivity than sputum smears in adults, and therefore the diagnosis often rely 
on an epidemiological history of an adult being diagnosed of TB.  
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The most frequent bacterial and OI in the pre HAART era in children were severe bacterial 
infections (bacteraemia and pneumonia), herpes zoster, Pneumocystis jirovecii pneumonia, 
esophageal candidiasis and disseminated Mycobaterium avium complex (MAC), less common 
were cryptosporidiasis, tuberculosis (TB), systemic fungal infections and 
toxoplasmosis.(Dankner et al., 2001). The widespread use of HAART has decreased the 
incidence of bacterial infections and OI in children. Some of the opportunistic infections 
complicating HIV are not curable with available treatments, effective HAART has resulted 
in improved immune status leading to control the infection. (Gona et al., 2006) Early 
diagnosis, primary prophylaxis and antiretroviral treatment in vertically infected children 
are of major importance. The recommendation to start HAART in children has shifted 
towards an earlier initiation, to include infants less than 2 years in WHO guidelines in 
developing countries and in less than one year old in American and European guidelines, 
independently of immunological stage (WHO, 2010; CDC, 2010; PENTA, 2009). 
Primary and secondary prophylaxis is important to prevent OI in children. All children 
below 1 year old must to receive primary prophylaxis for PCP, children aged 1 to 4 years 
should receive it if they have a CD4 count below 20% of total lymphocyte count. Children 
aged 5 and above should receive such prophylaxis if they have a CD4 count below 200-250 
cells/mm3 or less than 15%. There are few data for recommendations for prophylaxis of 
other OI. Secondary prophylaxis is used after the treatment of some opportunistic infections 
to prevent the reactivation or re-infection. Discontinuation of primary prophylaxis for 
Pneumocystis jirovecci and other OI is possible and safe when immune reconstitution is 
reached. 
Vaccines are other important tool to prevent potential severe infections in HIV-infected 
children, including varicella and human papillomavirus vaccine. Recent evidence shows 
that children who were already HIV-infected when vaccinated with BCG at birth, and who 
later developed AIDS, were at increased risk of developing disseminated BCG disease. This 
has changed the recommendations for not using this vaccine in countries with a high 
burden of TB, until a diagnosis of HIV-infection has been ruled out. Live attenuated 
vaccines are not recommended in children with severe immunosuppresion, those with CD4 
cells percentage less than 15%.  
As patients are living longer, other infections have assumed more importance in the 
prognosis, as has been well documented with viral hepatitis in co-infected adults. 
Improvement in the immune system after the introduction of HAART, even in the absence 
of complete viral suppression, may serve as prevention and therapy for many AIDS-
defining OI, particularly those lacking effective therapy. With the immune boost achieved 
shortly after the initiation of HAART, a new immune reconstitution inflammatory 
syndrome (IRIS) has emerged. IRIS occurs shortly after the initiation of HAART due to an 
exaggerated inflammatory response. It is less well characterized in children than adults. The 
incidence is higher in children with low CD4 count and in developing countries. It is 
common in infants immunized with Bacille Calmette-Guerin (BCG) vaccine. Typically, IRIS 
occurs between 2 and 6 weeks after the introduction of HAART, but may occur up to 7 
months later. This syndrome consists of an exacerbation of signs and symptoms associated 
with the underlying disease, of infectious and non-infectious etiology, resulting in an 
apparent clinical worsening. IRIS result from a rapid rebound in immune function that 
respond to a variety of clinically occult or latent infections that were present at the time of 
initiation of HAART, not previously recognized by a severely dysfunctional immune 
system. IRIS can complicate the management of these children.  
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It is important to distinguish between failure in HAART, failure in treatment of an OI and 
antimicrobial resistance or compliance. If an OI becomes apparent in the first 12 weeks of 
HAART initiation and there is a suspicion, HAART must be continued and treatment for the 
OI started. When an OI present after 12 weeks on HAART with virologic and 
immunological responses, it may be either IRIS or manifestations of the OI with partial 
immune reconstitution that have not controlled the infection. In the last situation HAART 
should be continued and treated accordingly. If an OI occurred in the setting of a virologic 
and immunological failure on HAART, this regimen must be revaluated while treatment for 
the OI given as early as possible. 
The time of initiate HAART when an OI is present is unknown. The risk of complications 
associated with some antiretrovirals, the drug-drug interactions that make more difficult the 
management and the confusion with IRIS syndrome has led to suggest, in some 
circumstances, to wait some time before HAART initiation. Some OI improve with the early 
use of HAART. In other infections, like cryptococcal meningitis, it is recommended to wait a 
response to therapy to start HAART. In general, HAART should be initiated early after the 
OI has been diagnosed. Recently, a trial conducted in South Africa showed that the initiation 
of HAART simultaneously with TB treatment significantly improved survival. 
In HIV infected children other difficulty is that the pharmacokinetics data of many 
commonly used drugs are incompletely known and the potential interactions between the 
different antiretrovirals and the drugs used to treat the OI may be significant, reducing the 
number of options available for treatment (CDC, 2009). 
2.2.1 Impact of HAART on bacterial infections  
During pre-HAART era, serious bacterial infections were the most commonly diagnosed 
infections in HIV-infected children. Pneumonia was the most common bacterial infection 
followed by bacteraemia and urinary tract infection. Other serious bacterial infectious 
including osteomyelitis, meningitis, abscess and septic arthritis occurred as well. HIV-
infected children are at risk of serious bacterial infections during the early years of life, and 
in these patients the risk is magnified by the direct effects of HIV related with T and B cell 
dysfunction. The most common blood isolate organism among HIV-infected children is 
Streptococcus pneumoniae. A significant decrease in bacteraemia incidence and the time to 
first bacteraemia incident were seen in the post HAART era. In pre-HAART era children 
with a decline of CD4 T cells were more likely to develop bacteraemia, and children who 
experienced bacteraemia had an associated higher mortality (Kapogiannis et al., 2008). In era 
post-HAART the bacteraemia has decreased but the incidence remains substantially higher 
than in HIV-uninfected children. There are no data currently on whether initiation of 
HAART during acute sepsis reduces short-term morbidity or mortality. Paediatric HIV 
infection is not a homogeneous condition in the era of HAART. Susceptibility to sepsis 
differs according to stage of disease, access to HAART, and virologic and immunologic 
response to treatment. HIV-infected children have higher risk of developing pneumonia and 
of more severe disease than immunocompetent children. Pneumonia remains a major cause 
of death and hospitalization, particularly in developing countries. HAART has 
demonstrated to decrease the incidence of pneumonia. The vaccine, early HAART and 
antibiotic prophylaxis are preventive strategies to prevent pneumonia (Gray & Zar, 2010). 
The prophylaxis with vaccination is important in these children and prophylaxis with 
Trimethoprim-sulphametoxazole (TMP-SMX) produce a benefit to reduce the incidence of 
www.intechopen.com
 
Microbes, Viruses and Parasites in AIDS Process 
 
10
these infections. In developing countries where the access to HAART is limited, these 
children can benefit from prophylaxis with TMP-SMX to avoid bacterial infectious. The 
WHO recommends prolonged daily prophylaxis for HIV-infected infants and children. 
Intermittent prophylaxis was associated with more invasive bacterial disease than daily 
prophylaxis, but the survival was similar (Zar et al., 2010). Opportunistic infections 
prophylaxis can be withdrawn safely for HIV-infected patients who experience CD4 cell 
recovery while receiving stable antiretroviral therapy, no increase in the rate of serious 
bacterial infection was observed. (Nachman et al., 2005). 
2.2.2 Impact of HAART on opportunistic infections  
Oropharyngeal candidiasis continues to be one of the most frequent opportunistic infection 
in HIV-infected children and often present as an initial manifestation of the disease. 
Oesophageal or pulmonary candidiasis has decreased after introduction of HAART. In 
children who not respond to HAART, candida esophagitis can occur and be concomitant to 
another opportunistic infection. Disseminated candidiasis is rare among HIV-infected 
children. There are no data in children to make recommendations for treatment or 
prevention of oropharyngeal candidiasis. With the available data from adults no conclusion 
can be made about the effectiveness of what antifungal is better for prophylaxis, although 
fluconazole is better than placebo. Ketoconazole, fluconazole, itraconazole and clotrimazole 
improved the treatment outcomes (Pienaar et al., 2010). 
Cytomegalovirus infection can be acquired during infancy, early childhood or adolescence. 
HIV-infected women with CMV infection have a higher rate of CMV shedding from the 
cervix than do women without HIV infection and the risk for mother to infant transmission 
of CMV may increased among infants born to women infected by both CMV and HIV. After 
being born, HIV-infected children have higher risk for CMV infection (Schleiss MR, 2009). In 
era pre HAART co-infection appear to have faster progression of HIV disease. CMV retinitis 
is a frequent manifestation in HIV infected children. Viral dissemination can affect multiple 
organs producing pneumonitis, gastrointestinal disease and involvement of the central 
nervous system. Disseminated disease and retinitis must be treated with induction therapy 
and after chronic suppressive therapy. The safety of discontinuation of secondary 
prophylaxis in children with retinitis has not been well studied, but if the child has 
completed 6 months of HAART and the CD4  count are >15% in children 1-5 years old or > 
100 cells/mm3 in older than 6 years, secondary prophylaxis is usually withdrawn safely. 
HSV-1 (Herpes simplex virus-1) causes gingivostomatitis in HIV-infected children when they 
experiment the primary infection by contact with infected oral secretions. If the patient is 
severely immunocompromised the HSV-1 may produce severe local lesions or disseminated 
infection with visceral involvement like esophagus, CNS, lung, spleen, liver and kidney. 
HAART has decreased the rates of systemic HSV infection. The HIV infected children can 
also have recurrences of gingivostomatitis. Neonatal transmission occurs with the exposure 
to maternal genital fluids. Congenital HSV infection is rare but it has cutaneous, ocular and 
CNS involvement. Caesarean delivery must be considered in women with active genital 
HSV. HSV-2 is acquired in adolescents by contact with infected genital secretions and the 
risk of genital HSV reactivation increases with the immunosupresion. HSV infection can 
increase the risk for mother to child HIV transmission. The treatment is acyclovir orally or 
intravenously depending on the severity of the infection. Valacyclovir, a prodrug of 
acyclovir, can also be effective. 
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The virus varicella zoster (VZV) is associated with more severe disease in HIV infected 
children in pre-HAART era than in uninfected children. After HAART and vaccination the 
rates of varicella has decreased. In some cases, disseminated varicella can develop in 
children with severe immunocompromise, but not in children with higher CD4. Retinitis can 
be a complication of varicella. Herpes zoster after infection of varicella is described like a 
decline in specific cellular immunity to VZV and can involve various dermatomes. HIV-
infected children before HAART with low CD4 percentage at the time of primary varicella 
were at higher risk to subsequent zoster. In HIV-1 infected children the incidence of herpes 
zoster was higher in advances stages of immunusuppression. It has been reported an 
increase of herpes zoster after the introduction of HAART, but the incidence is less than pre-
HAART era, possible due to vaccination. (Levin et al., 2009) A VZV-associated IRIS has been 
described after 1-3 months after the introduction of HAART with mild cutaneous 
manifestations and with the distribution by dermatomes, responding to acyclovir 
(Puthanakit et al., 2006). The treatment of choice is acyclovir, other alternatives are 
valacyclovir or famciclovir. The prevention for varicella in a contact must be the vaccination 
or varicella zoster immunoglobulin, in some cases acyclovir can be used. 
Congenital toxoplasmosis has been rarely reported in HIV-infected children. It may occur 
when a HIV-mother acquired the primary Toxoplasma infection during the pregnancy, 
although perinatal transmission has been described in women with chronic Toxoplasma 
infection because the reactivation of replication in women with severe immunosupresion. The 
symptoms in congenital infection are generalized lymphadenopathy, hepatosplenomegaly, 
jaundice, hematologic abnormalities and CNS disease. CNS disease in HIV-infected children 
acquired after the delivery is very rare, and this occur like in adults when the CD4 were less 
than 50 cells/mm3, but in HIV-infected children with neurologic symptoms, it must be 
considered. Ocular toxoplasmosis often is associated with CNS infection. Mother with acute 
toxoplasmosis must be treated and empiric therapy in newborn initiated. The treatment in 
congenital toxoplasmosis is pyrimethamine combined with sulfadiazine with folinic acid with 
a recommended duration of 12 months. Cerebral toxoplasmosis should be treated during 6 
weeks depending of the evolution. Corticosteroids and anticonvulsants may be necessary. 
Primary prophylaxis must be done with TMP-SMX in children with CD4<15% in children 
under 6 years old or CD4 < 100 cells/mm3 or older than 6. Discontinued primary prophylaxis 
is possible when the immune restoration occurs. Secondary prophylaxis must be used until 
immune reconstitution with HAART is initiated, then discontinuation of secondary 
prophylaxis must be considered.    
Cryptococcosis occurs less frequent in children than in adults. In era pre-HAART 
cryptococcosis cases were in older children and with severe immunosuppression. In the 
HAART era the rate of this infection has decreased, remaining uncommon. The clinical 
manifestations of this infection are meningoencephlalitis, pulmonary or disseminated 
infection. The treatment is therapy of induction during 2 weeks with amphotericin B or 
liposomal amphotericin B and flucytosine in CNS disease and after the consolidation 
therapy during 8 weeks with fluconazole.  When CNS is not affected the flucytosine may not 
be used. Fluconazole is used to prevent recurrences. If a restoration of immune status is 
produced by HAART, fluconazole can be discontinued. In some cases IRIS may develop 
when HAART is initiated simultaneously and therefore it is recommended to delay 
HAART, but if the patient is on HAART previously, this must be continued.    
Cryptosporidiosis/isosporidiosis have declined dramatically after HAART. Before HAART 
these infections occurred with advanced immunosupresion. Although the incidence of these 
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parasitic infections has declined with HAART, developing countries with less access to 
HAART have high incidence of these infections. Watery diarrhea is the most common 
manifestation of crypstosporidium, that can migrate into bile duct resulting in inflammation 
and slerosing cholangitis. Pancreatitis occurs rarely. Effective HAART is the main treatment 
for these infections. In crypstosporidiosis a 3-day course of nitazoxanide significantly 
improved the resolution of diarrhoea, parasitological eradication, and mortality in HIV 
seronegative, but not HIV seropositive, children (Amadi et al., 2002). IRIS has not been 
described with cryptosporidiosis treatment. 
The incidence of tuberculosis depends on the site, and where the incidence of tuberculosis is 
high, it depends on the age and is increased in HIV co-infected children.  So in sub-Saharan 
countries the incidence rate in HIV-children below 12 months of age is 1595/100.000   
compared with 659/100.000 in HIV-uninfected. In older than 12 months-old the incidence 
rate is 5930/100.000 in HIV-infected children (Verhagen et al., 2010). The resistance of 
tuberculosis is increasing and it is an obstacle to control the TB worldwide. The diagnosis in 
children is more difficult than in adults due to the difficulty to obtain a smear of bronchial 
secretions for a bacteriologic diagnosis. The tuberculin skin test (TST) in HIV-infected 
children with tuberculosis disease can be negative. Recently, an IFN-γ release assay from 
lymphocytes after stimulation by highly specific synthetic Mycobacterium tuberculosis 
antigens has been developed, which sensitivity is higher than TST, but is commonly leads to 
indeterminate results in young and immunocompromised children. To obtain a specimen 
for microbiologic diagnosis is more combersome in children because of their difficulty in 
producing sputum, so there is a need to rely on gastric aspirates, although hypertone saline 
induced sputum induction has shown good results (Zar et al., 2005). The microbiological 
diagnosis relies on microscopic acid-fast bacilli staining, the isolation the mycobacteria in 
the culture, and recently nucleic acid amplification can improve the diagnostic yield. Drugs 
susceptibility testing is important due to increasing resistance. It is recommended a 
standardization of clinical and radiographic case definition to avoid confusion in the 
diagnosis. To prevent M. tuberculosis infection, BCG vaccine is not currently used due to the 
risk of disseminated disease in HIV-infected children (WHO, 2007). Treatment of latent 
tuberculosis infection is indicated in HIV infected children with isoniazide, if resistance to 
this drug is not suspected in the source case. There are insufficient data to guide isoniazide 
prophylaxis in HIV-infected children in high-prevalence countries in the absence of TB 
exposure (Gray et al., 2009).  In HIV-infected children with TB disease, initiation of TB 
treatment is the priority although the optimal timing of HAART initiation is uncertain. 
Recently, a trial conducted in South Africa in adults showed that the initiation of HAART 
simultaneous with TB treatment significantly improve survival. (Abdool et al., 2010). 
Rifampin is a potent induction of the CPY3A that precludes treatment with all protease 
inhibitors (IP) but may allow the treatment with non-nucleoside reverse transcriptase 
inhibitors (NNRTIs). In many countries of Africa a PI-based antiretroviral regimen is 
indicated in HIV-infected children less than 36 months like first line regimen: in children 
older than 3 years IP can be replaced by efavirenz to avoid interactions with TB treatment; in 
younger than 3 years efavirenz can be replaced by nevirapine however there is a high 
percentage of resistance in children exposed to single dose nevirapine used for prevention 
of mother to child transmission (PMTCT). The management of TB resistance in cases of 
MDR and XDR TB must be guided by expert based on guidelines (WHO, 2008) (CDC, 2007). 
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IRIS has been described in children and must be suspected in children with advanced 
immunosupression who start HAART. TB therapy must not be discontinued and 
symptomatic treatment can be used including corticosteroids. BCG IRIS has been reported 
in children initiating HAART. 
Mycobacterium avium complex (MAC) disease is caused by multiple species of nontuberculous 
mycobacteria. The incidence has decreased after introduction of HAART. MAC produces 
lymphadenitis and a disseminated infection in children with advanced immunologic 
deterioration. The main treatment is to preserve the immune function with HAART. The 
specific treatment is combined therapy with a minimum of 2 drugs. IRIS may occur, so 
antimycobacterial therapy should be started 2 weeks before HAART to minimize the IRIS 
symptoms. The chronic suppressive therapy may be safely discontinued if immune 
reconstitution is reached. 
Pneumocystis jirovecii pneumonia has decreased in HAART era. Around 80% of 
immunocompetent children have acquired antibodies for Pneumocystis by the age of 2-4 
years, and the infection is usually asymptomatic or presenting with mild respiratory 
symptoms. However, in HIV-infected children the infection frequently is very severe 
associated with high mortality, being an AIDS event occurring in the first year of life 
between 3-6 moths. HAART and prophylaxis for Pneumocystis has decreased the incidence. 
Pneumocystis pneumonia depends of the grade of immunosupression of the child, so marked 
decrease in CD4 is a risk factor for this. Pneumocystis pneumonia is characterized by fever, 
tachypnea, cough with hypoxia low arterial oxygen pressure, lactic dehydrogenase is often 
increased and the radiography can indicate bilateral diffuse parenchymal infiltrates. The 
microbiologic diagnosis is based on the identification of Pneumocystis in respiratory 
secretions. Bronchoalveolar lavage is the procedure of choice with a high diagnostic yield in 
HIV-infected children. Coinfection by other microorganisms must be considered. 
Prophylaxis is recommended in all the children since 4-6 weeks of age during the first year 
of age independently of CD4 count, with TMP-SMX. Infants with indeterminate HIV 
infection must received prophylaxis until they are confirmed to be non-infected. In older 
children prophylaxis is indicated if the CD4 are less than 15%. TMP-SMX is also effective to 
prevent toxoplasmosis and bacterial infections. The treatment is with TMP-SMX 
intravenously during 21 days. IRIS is rare to occur with this infection. Adverse reactions are 
frequent with TMP-SMX so other drugs must be considered. In cases of severe infection 
corticosteroids must be considered starting in the first 72 hours of diagnosis.   
2.2.3 Impact of HAART in other infections 
Malaria and HIV infection are two infections with a similar distribution in most countries, 
mainly in sub-Saharan Africa. An increased susceptibility in HIV-infected patients has been 
described in adults due to impaired immune response to malaria through cellular 
immunosuppression resulting in a higher likelihood of increased parasitaemia and severe 
malarial infections. HIV infection increases the incidence of clinical malaria, inversely 
correlated with the degree of immunodepression. HIV infection is associated with an increase 
of cerebral malaria (Imani et al., 2011). The effect of malaria on HIV infection is not as well 
established. Malaria, when fever and parasitemia are high, may be associated with transient 
increases in HIV viral load. The effect of subclinical malaria on HIV viral load is uncertain. 
TMP-SMX may be effective in the prevention of malaria but the development of resistance is 
of concern.  Severe malaria is clinically similar to other severe febrile illnesses. However, in 
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endemic areas, parasitological confirmation of parasitaemia is often unavailable or 
unreliable and false positive malaria microscopy is common. The routine use of parenteral 
antibiotics among children with a positive malaria slide and life-threatening disease is 
warranted because invasive bacterial infections are likely to be overlooked and are 
associated with increased mortality. During pregnancy, placental malaria is associated with 
higher plasma and placental HIV viral loads, independently of the severity of 
immunodeficiency. Both infections have been associated with maternal and infant morbidity 
and mortality (Brentlinger et al., 2006)). HIV-1 exposure and HIV-1 infection are associated 
with increased prevalence of severe malarial anaemia during acute P. falciparum infection, 
independent of parasite density. HIV infection status does not affect the choice of therapy 
and no recommendations exist for alternative dosing of antimalarial drugs in HIV-infected 
persons. IRIS caused by malaria has been not reported. 
HBV-HIV co-infection in children is less frequent nowadays in developed countries since 
the universal policy o HBV vaccination to newborns. Nevetheless, HBV is still a major 
problem in developing countries.  
The clearance rates in HBV monoinfected children are 10% in newborns, 70% in children 1-5 
years old, and 94% in >5 years. Chronic hepatitis is defined as persistence of HBsAg for 
more than 6 months. Children can acquire the infection perinatally, parenterally or through 
sexual transmission. Most children with chronic HBV infection are asymptomatic. They can 
develop cirrhosis and hepatocellular carcinoma over 2 or 3 decades. The diagnosis is made 
by detection of HBsAg. HBeAg seroconversion is defined as loss of HBeAg followed by the 
production of antibodies to HBeAg (anti-HBe) and is defined as an inactive carrier state. 
HBV DNA is a marker of replication of HBV. Biopsy determines the grade of hepatic 
inflammation and fibrosis by metavir classification. Percutaneous transient elastography 
(Fibroscan) is less aggressive than biopsy and useful to determine the grade of inflammation 
and fibrosis of the liver.  The indications for treatment of chronic HBV in HIV co-infected 
children include evidence of HBV viral replication indicated by detectable serum HBV 
DNA, with or without HBeAg positivity, for >6 months, persistent elevation of serum 
transaminase levels or evidence of chronic hepatitis on liver biopsy. Treatment is not 
recommended for children with immunotolerant chronic HBV infection (i.e., normal serum 
transaminase levels despite detectable HBV DNA). After initiation of HAART, liver function 
may worsen due to immune reconstitution syndrome causing an increased immune 
response to HBV in the liver and subsequently a “flare” of hepatitis. HBV itself, however, 
has no detrimental effect on the course of the HIV infection.   
HCV-HIV co-infection occurs approximately in 30% of adults. Vertical transmission of HCV 
is 3-5 fold higher in HIV-HCV co-infected mothers. HCV can be accelerate the progression 
of HIV infection increasing the viral replication, produce a worse immune reconstitution 
and there is an increase of hepatic toxicity. HIV influences in HCV infection increasing the 
progression of the liver disease. In HIV-HCV coinfection liver pathology develops more 
rapidly than in HCV mono-infection. The HCV is usually asymptomatic. Chronic HCV 
infection is defined as the presence of HCV RNA for > 6 months. In perinatally-acquired 
HCV-infected children, 20% had apparent clearance of infection, 50% had chronic 
asymptomatic infection and 30% had chronic active infection. During the infancy there 
might be an immunotolerance to this infection. The diagnosis is by serologic antibodies but 
these can be persistently negative in HIV-infected children. Therefore, HCV RNA qualitative 
or quantitative should be used for diagnosis of infection. HCV viral load does not correlate 
with the degree of liver damage. There are different   genotypes of HCV, genotypes 2 and 3 
are more likely than 1 or 4 to achieve sustained virologic response to treatment. The biopsy 
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or fibroscan are used to know the grade of inflammation or fibrosis of the liver. The 
indications for HCV treatment can be detectable HCV-RNA, persistent elevation of 
transaminases, evidence of chronic hepatitis on liver biopsy, children >3 years old and no 
decompensated liver disease. The treatment accepted in children is standard interferon-alfa-
2b with ribavirin. Pegilated interferon-alfa administered for 24-48 weeks with ribavirin is 
recommended in adults. Although, the experience of HCV treatment in coinfected children 
is scarce, (Navarro et al., 2007) and there is a need of studies. HAART should be initiated. 
HAART should be initiated earlier than in non-HCV infected children 
2.2.4 Immune Reconstitution Inflamatory Syndrome (IRIS) 
Antiretroviral therapy improves immune function and CD4 cell count in HIV-infected children 
within the first few months after starting HAART producing an increase of CD4 cells and 
decrease in viral load. This changes are associated with an increase in the capacity to develop 
inflammatory reactions. Some patients develop a paradoxical inflammatory response by their 
reconstituted immune system to infectious or non-infectious antigens, resulting in apparent 
clinical worsening. There are two types of IRIS: ¨unmasking¨ IRIS and ¨paradoxical¨ IRIS. The 
unmasking IRIS is an occult and subclinical opportunistic infection, unmasked by immune 
recovery following the HAART initiation. Paradoxical IRIS is a clinical recrudescence of a 
successfully treated infection, symptomatic relapse despite initial clinical improvement and 
continued microbiologic treatment success; the antigen driving the immune activation often 
elicits a robust immune response in the setting of few or no detectable organism and the 
culture may be sterile due to effective opportunistic infection treatment. 
The criteria for diagnosis of paediatric IRIS are: a) evidence of clinical response to ART with 
a virologic response with > 1 log10 copies/ml, decrease in HIV RNA; b) clinical deterioration 
from an infectious or inflammatory condition temporally related to the initiation of ART 
(unmasking or paradoxical); c) symptoms cannot be explained by an alternative infection or 
neoplasm, treatment failure of the opportunistic infection, adverse drug reaction or 
complete non-compliance to ART or TB treatment. 
The commonest causes are mostly mycobacterial, including tuberculosis, atypical 
mycobacteria and BCG-related and herpes zoster. 
The incidence of IRIS is between 10-20% in developing countries. IRIS often occurs in older 
children who start HAART with an advanced stage of immunosupresion, although in young 
infants it may also occur. Risk factors for IRIS include a high pathogen load and very low 
CD4 cell count when HAART is initiated. Many children have a marked mortality within 
the first 90 days of HAART. 
The treatment of ¨unmasking¨ IRIS is the treatment of the underlying opportunistic 
infection, in some cases also anti-inflammatory therapy and rarely discontinuation of 
HAART. Screening of occult infections before starting HAART can reduce IRIS. The 
treatment of ¨paradoxical¨ IRIS is observation in mild cases, non-steroidal anti-inflamatory 
drugs in moderate reactions, and corticosteroids in severe cases, considering the temporary 
cessation of HAART and surgical debulking (Boulware et al., 2008). 
When a child starts HAART, is difficult to distinguish between HAART toxicity, from 
toxicity due to treatment to the opportunistic infection and IRIS. Opportunistic infections 
can occur in HIV-infected children experiencing virologic and immunologic failure on 
HAART. If symptoms appeared within the 12 weeks after initiation HAART, it may indicate 
¨unmasking IRIS¨, so HAART must be continued and opportunistic infection treatment 
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initiated. If symptoms occurred after 12 weeks and there is immunologic and virologic 
response, it may be due to ¨paradoxical IRIS¨ or incomplete immune reconstitution allowing 
a new opportunistic infection. In both cases HAART must be continued and if the 
microbiologic evaluation demonstrates a microorganism, it should be treated.  
2.2.5 Prophylaxis and vaccines 
2.2.5.1 Prophylaxis 
TMP-SMX prophylaxis is indicated in HIV-infected children since 4-6 weeks of age until the 
first year of life and in older children with CD4 less than 15%.  TMP-SMX prophylaxis is 
indicated to prevent Pneumocystis jirovecci pneumonia but it has activity against a wide 
range of pathogens including Pneumococcus, non-typhoidal Salmonella, Isospora, Cyclospora, 
Nocardia, Plasmodium falciparum and Toxoplasma gondii. In developing countries, the CHAP 
study, a randomized study placebo-controlled trial of cotrimoxazole in Zambia, showed the 
impact of TMP-SMX on reducing mortality in HIV infected children from 6 months to 14 
years (Chintu et al., 2004). WHO guidelines on co-trimoxazole prophylaxis published in 
2006, recommend prophylaxis in infants less than 1 year until infection can be excluded or 
until 6 weeks after the cessation of breastfeeding (WHO, 2006). TMP-SMX prophylaxis has 
potential risk of resistance and side effects. Currently the number of HIV-infants children 
infected is decreasing due to the interventions to prevent mother to child transmission and 
WHO now recommend that breastfeeding women receive HAART or the infants receive 
nevirapine prophylaxis. Thus, a lower number of children are expected to become HIV-
infected and to receive prophylaxis. Breastfeeding decreased the risk of infections such 
diarrhoea and pneumonia due to the immune protection. These preventive options and the 
molecular tests are more accessible in these countries, allows limiting the prophylaxis for the 
uninfected infants (Coutsoudis et al., 2010). WHO guidelines for HIV-infected children of 1-
4 years recommend prophylaxis if they are symptomatic or have less than 25%.  Similarly, 
the infants who start prophylaxis before the age of one and who subsequently are 
asymptomatic and/or have CD4> 25% should remain on co-trimoxazole prophylaxis until 
they reach five years old. In older than 5 years the recommendations are similar than adults. 
A randomized controlled trial has compared daily versus intermittent prophylaxis in South 
Africa, finding that the intermittent prophylaxis was associated with more invasive bacterial 
disease than daily prophylaxis, but survival was similar (Zar et al., 2010).  
TMP-SMX has a range of side effects like skin rashes, gastrointestinal disturbances and 
marrow suppression which lead to neutropenia and anaemia, in rare cases Stevens-Johnson 
syndrome may occur. In adults has been studied when there is a hypersensitivity to co-
trimoxazole, the management of these adverse reactions has included continuing the drug 
(treating-through) and reintroducing the drug at a later date, either using dose-escalation 
(desensitization), or rechallenge at full dose. It observed that cotrimoxazole desensitization 
resulted in better outcome. Data in children are required (Lin et al., 2007). 
Discontinuation of primary and secondary prophylaxis with TMP-SMX in children is 
possible if a restoration of immune system has occurred (Urchel et al., 2005). Studies have 
studied the incidence of serious bacterial infections after the withdrawal of prophylaxis 
(Nachman et al., 2005).    
2.2.5.2 Vaccines 
HIV-infected children are at increased risk of infections, particularly invasive bacterial 
infections due to encapsulated bacteria. Cotrimoxazole prophylaxis and associated HAART 
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have shown improvements in morbidity and mortality in HIV-infected children. (Walker et 
al, 2007). However, even in the ART era, HIV infected children have increased susceptibility 
to vaccine preventable diseases.  
Routine immunizations are generally well tolerated by HIV-infected children but vaccine 
safety remains an important issue. There have been concerns that vaccination itself could 
result in immunologic deterioration. Although plasma viral loads could be temporally 
increased after vaccination, no evidence of HIV disease progression has been observed. 
Recent evidence shows that children who were already HIV-infected when vaccinated with 
bacille Calmette-Guérin (BCG) at birth, and who later developed AIDS, were at increased 
risk of developing disseminated BCG disease. Among HIV-infected infants, the benefits of 
potentially preventing severe tuberculosis therefore appear to be outweighed by the risks 
associated with the use of BCG vaccine. In 2007, HIV infection in infants was considered a 
full contraindication to BCG vaccination in the new revised World Health Organization 
guidelines (WHO, 2007). Live viral vaccines (eg. varicella, mumps, measles and rubella) are 
generally not contraindicated in children who have stable CD4 status and not have severe 
immune suppression.  
HIV-infected children in the pre-HAART era had poorer responses to vaccines and more 
rapid waning of immunity. Lower CD4 cell counts, higher viral load, age or advanced HIV 
stage at vaccination, have been associated with the immunity response, although these risk 
factors have not been consistent across the studies. HAART is effective in HIV-infected 
children by suppressing viral replication and restoring immune function. However, HAART 
is unlikely to restore memory T cells for vaccine antigens to which children were exposed 
before treatment. Previously vaccinated children showed low levels of immunity after being 
started on HAART. No epidemiological, virological or immunological factors consistently 
predicted immunity after starting HAART in these children. There is increasing evidence of 
improved immunization responses following effective HAART (Sutcliffe & Moss, 2010).  
Once children are commenced on ART, it is generally recommended to initiate vaccination 
or revaccination 6 months after CD4 cells recovery to the normal range of age. This 
recommendation is based on the progressive but not immediate immune recovery of HIV-
infected children starting HAART (Weinberg, 2008). Nowadays, it is recommended in 
children who were vaccinated before starting on HAART to measure the immune response 
to previous vaccines to guide the need for further doses. If non protective antibody levels 
are demonstrated; booster doses or revaccination should be considered, based on the 
response after one booster dose. Some benefit may be gained from vaccination even when 
severe immunosupression, so this should be especially considered for high risk patients. 
Complete revaccination after immune reconstitution is recommended. Although most 
children on HAART respond to vaccination, immune reconstitution is not sufficient to 
ensure long-term immunity for some children. These suggest that children on HAART 
would benefit from revaccination.  
Age of the patient when started on HAART might be important in enhancing vaccine 
responses. Early administration of HAART preserved the memory B-cell compartment. 
Children who were started on HAART in infancy, less than 12 months of age, had greater 
protective immunity that did children who were started on HAART later in childhood, and 
had similar levels of immunity compared with uninfected children of the same age 
(Pensieroso, 2009). These findings support recommendations for early administration of 
HAART among infants.  
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It is currently recommended to start vaccination of HIV-infected children in infancy with 
some modifications of the routine immunization schedule: 
- Hepatitis B virus (HBV) immunization in a four-dose-schedule starting soon after birth is 
recommended. Standard doses are advised as the infant should not be immunocompromised 
at this age. Testing for adequate seroconversion at or after the time of the fourth dose is 
important. Booster dose o revaccination is recommended accordingly to anti-HBs titre for 
protection. Newborns of HBV-coinfected mothers also require one dose of anti-HBV 
immunoglobulin with the first dose of HBV vaccine.  
- Diphteria, tetanus and acellular pertussis vaccine (DTPa) is recommended in a five-
dose-schedule as in routine vaccination programs. One dose of dTpa adult vaccine (low 
dose diphtheria and pertussis) is recommended for adolescents who have completed 
the series of DTPa in childhood. Revaccination with dTpa is recommended every 10 
years for adults.  
- Four doses of parenteral polio vaccine (IPV) and Haemophilus influenzae type b (Hib) 
are recommended as in routine immunization programs. Hib vaccine could be 
considered in HIV-infected children more than 5 years old who did not receive the 
vaccine before. 
- Meningococcal C vaccine is recommended in a three dose scheme in first year of life. It 
is also advised to vaccinate older HIV infected children with two doses, especially 
adolescents who have not been vaccinated before.   
- A 3 dose primary immunization schedule of conjugate 13-valent pneumococcal vaccine 
(PCV13) in the first year of life is recommended, with a re-enforcing dose during the 
second year. The first dose of polysaccharide 23-valent pneumococcal vaccine (PPV23) 
is recommended after 24 moths old and at least 2 months after the final dose of PCV13. 
Revaccination with PPV23 every 5 years thereafter should be considered. For children 
aged 24 months or more, who have not been vaccinated against pneumococcal disease, 
2 doses of PCV13 administered at least 2 months apart, and later PPV23 immunization 
schedule is recommended.  
- Hepatitis A virus (HAV) vaccine could be considered in a two dose scheme for all 
hepatitis A seronegative HIV-infected children over 12 months of age, especially 
focussing on adolescents or populations with high endemic or epidemic diseases.  
- Measles, mumps and rubella (MMR) vaccine is recommended in a two dose schedule 
unless there is evidence of severe immunocompromise (CD4 cell percentage < 15%).   
- Varicella vaccine is indicated in two dose schedule in HIV-infected children more than 
12 moths of age, in CDC clinical class N, A or B with CD4 threshold as stated for MMR 
vaccination and without evidence of varicella immunity.  
- Live-attenuated human rotavirus vaccine have been studied in HIV infected infants, in 
clinical stages I and II according to WHO classification, in a three dose schedule  
starting on 6 to 10 weeks of age. The vaccine was safe and a satisfactory immune 
response was mounted without aggravating their immunologic or HIV condition 
(Steele, 2011). Although the data are limited, this vaccine could be considered in HIV 
infected infants within the routine age range recommended in HIV healthy infants.  
- Human papillomavirus (HPV) vaccine. Data of quadrivalent human papillomavirus 
vaccine (QHPV) in HIV-infected children (60% female) aged from 7 to 12 years, with a 
CD4% ≥15 and on stable antiretroviral therapy showed that the vaccine is safe and 
immunogenic for the 4 antigens (Levin, 2010). Although the data are limited, this 
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vaccine is recommended for girls from 12 years of age (minimum age 9, maximum age 
26 years), irrespective of CD4 count in a 3 dose schedule. 
- Trivalent inactivated influenza vaccine is recommended yearly from 6 months of age. 
Vaccination schedule and doses are similar to those recommended for healthy children 
and adolescents. 
3. Conclusion  
HAART has dramatically decreased the incidence of opportunistic infections in children and 
organ-specific diseases in developed countries. Opportunistic infections may complicate the 
treatment of HIV due to the disease itself, toxicity of the drugs and immune reconstitution 
inflammatory syndrome. HAART, prophylaxis, vaccines help to reduce the incidence of 
opportunistic infections. However in developing countries where there is a greater number 
of new diagnosis of HIV-infected children, less access to antiretroviral drugs and higher 
prevalence of opportunistic infections like tuberculosis, the prevention and the treatment 
must to be a priority. 
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